JAN (NYSE:JAN) Stock Gets Price Target Reduction from Barclays

JAN (NYSE:JAN) had its price objective cut by Barclays from $34.00 to $33.00 in a research note issued to investors on Tuesday morning,Benzinga reports. They currently have an overweight rating on the stock.

JAN has been the subject of a number of other reports. Royal Bank Of Canada raised their target price on JAN from $30.00 to $34.00 and gave the stock an “outperform” rating in a research note on Monday, August 10th. Huntington initiated coverage on shares of JAN in a research report on Thursday, September 10th. They set an “outperform” rating and a $36.00 price target on the stock. Zacks Research raised shares of JAN from a “hold” rating to a “strong-buy” rating in a research report on Friday, October 9th. Compass Point assumed coverage on shares of JAN in a report on Wednesday, September 16th. They issued a “neutral” rating and a $37.00 price objective for the company. Finally, JPMorgan Chase & Co. raised their price objective on shares of JAN from $30.00 to $34.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 18th. Two research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $32.38.

JAN Stock Up 1.1%

NYSE:JAN opened at $29.29 on Tuesday. JAN has a one year low of $22.76 and a one year high of $32.83. The stock has a 50 day moving average price of $30.08 and a 200 day moving average price of $28.12.

JAN (NYSE:JAN) last announced its quarterly earnings data on Tuesday, August 4th. The company reported $0.05 EPS for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.18). The company had revenue of $216.46 million during the quarter, compared to analysts’ expectations of $203.32 million. The company’s quarterly revenue was up 45.4% on a year-over-year basis. JAN has set its FY 2026 guidance at 0.950-0.980 EPS. As a group, equities analysts forecast that JAN will post 0.97 earnings per share for the current fiscal year.

JAN Dividend Announcement

The firm also recently disclosed a monthly dividend, which will be paid on Tuesday, December 29th. Investors of record on Friday, December 18th will be issued a $0.0475 dividend. The ex-dividend date is Friday, December 18th. This represents a $0.57 dividend on an annualized basis and a yield of 1.9%.

Institutional Investors Weigh In On JAN

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Greenland Capital Management LP purchased a new stake in JAN in the second quarter valued at $575,000. State of Alaska Department of Revenue grew its holdings in shares of JAN by 57.6% during the 3rd quarter. State of Alaska Department of Revenue now owns 36,557 shares of the company’s stock worth $1,082,000 after purchasing an additional 13,367 shares during the period. Readystate Asset Management LP purchased a new position in shares of JAN during the 2nd quarter worth $1,724,000. WINTON GROUP Ltd acquired a new stake in shares of JAN during the 2nd quarter worth about $2,985,000. Finally, Wellington Management Group LLP acquired a new stake in shares of JAN during the 2nd quarter worth about $8,739,000. Institutional investors and hedge funds own 6.27% of the company’s stock.

JAN News Summary

Here are the key news stories impacting JAN this week:

• Negative Sentiment: Barclays issued a pessimistic forecast for JAN, potentially limiting near-term upside and raising concerns about the company’s earnings outlook. Barclays Issues Pessimistic Forecast for JAN Stock Price
• Positive Sentiment: JAN’s latest quarterly results showed strong top-line momentum, with revenue rising 45.4% year over year to $216.46 million and exceeding analyst expectations, while management maintained fiscal 2026 EPS guidance of $0.95 to $0.98.
• Neutral Sentiment: The company’s most recent quarter included an EPS miss, reporting $0.05 versus the consensus estimate of $0.23. Investors may therefore remain focused on whether revenue growth can translate into improved profitability.

About JAN

JanOne Inc (NYSE: JAN) is a publicly traded company focused on addressing the opioid crisis through the development and commercialization of solutions intended to improve the treatment and prevention of opioid use disorder. The company has described its mission as combining business, technology and scientific initiatives to help reduce opioid-related harm.

JanOne’s activities have included biotechnology and pharmaceutical-development initiatives, as well as investments in technologies and businesses connected with healthcare and financial services.